Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more
Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded by General Manager Yunshu Zhou. Zhou has served in various roles at the Lianyungang-based company since 1995. Hengrui markets a variety of drugs including classical Hodgkin lymphoma therapy camrelizumab (SHR-1210), an anti-PD-1 antibody, in China.
Olivier Brandicourt will join Blackstone Group as a senior adviser, a source familiar with the matter who wished to remain anonymous told BioCentury. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, joins the firm as it looks to raise the final $1.2 billion of its Life Sciences V fund, which has a $4.6 billion target. ...